drugset / Trial / NCT01320761
A Study to Assess Injection Comfort of Two Formulations of ATX-101
RandomizedCrossoverQuadruple-blindTreatment
Summary
To assess the safety and injection comfort of ATX-101-BA versus ATX-101-BA-free immediately following injection and at regular intervals up to 24-hours post-injection following subcutaneous administration into the submental area.
Timeline
- Start
- —
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ATX-101 | Peptide | — | Subcutaneous |
Indications
No indication recorded.